The recent label expansions by the FDA and European regulators for UCB SA's pegylated anti-TNF therapy, Cimzia (certolizumab pegol), in moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy turned still more attention to the shifting market, where TNF blockers are still favored for new patients but where other mechanisms of action continue to gain ground.